Andere talen Spago Nanomedical AB

Aandelen

SPAG

SE0004899474

Beurs gesloten - Nasdaq Stockholm Andere beurzen 15:52:18 02-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,358 ^SEK	-3,76%		+23,45%	+9,48%

24/04	Spago Nanomedical AB (publ) rapporteert gunstige gegevens in borstkankermodel met Tumorad	CI
16/04	Spago Nanomedical AB (publ) kondigt de benoeming aan van Birgitta Rembratt Svensson als hoofd van CMC & Supply, met ingang van 1 juni 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Spago Nanomedical : Interim ReportQ12024	02/05
Spago Nanomedical interim report January-March 2024	02/05
Spago Nanomedical AB Reports Favorable Data in Breast Cancer Model with Tumorad	24/04
Spago Nanomedical reports favorable data in breast cancer model with Tumorad	24/04
Spago Nanomedical strengthens management with Head of CMC and Supply	17/04
Spago Nanomedical strengthens management with Head of CMC & Supply	16/04
Spago Nanomedical AB Announces Appointment of Birgitta Rembratt Svensson as Head of CMC & Supply, Effective June 1, 2024	16/04
BioStock: Spago Nanomedical's CEO: "huge commercial opportunities are unfolding"	27/03
BioStock: 2023 springboard for Spago's radionuclide cancer therapy	09/02
Spago Nanomedical Q4 Update	08/02
Spago Nanomedical year-end report January-December, 2023	07/02
Spago Nanomedical AB Reports Earnings Results for the Full Year Ended December 31, 2023	07/02
Spago Nanomedical AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/02
The rights issue and the directed share issue to certain guarantors in Spago Nanomedical fully registered	25/01
Spago Nanomedical presents at Redeye's Fight Cancer event on January 24	19/01
Spago Nanomedical presents at Redeye’s Fight Cancer event on January 24	18/01
BioStock: Spago's phase I/IIa cancer trial progressing steadily	15/01
Spago Nanomedical Proceeds to the Next Dose Level in the Phase I/IIa Study Tumorad-01	10/01
Spago Nanomedical proceeds to the next dose level in the phase I/IIa study Tumorad-01	10/01
Spago Nanomedical - Update after funding and initiation of Tumorad	03/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Spago Nanomedical AB

Aandelen

SPAG

SE0004899474

Andere talen

Filters